Assenagon Asset Management S.A. bought a new position in Enovis Co. (NYSE:ENOV – Free Report) during the 4th quarter, ...

WILMINGTON, DE - Enovis (NYSE: ENOV), a prominent medical technology company with a market capitalization of $2.54 billion, has announced the appointment of Davide Visentin as the new President of ...

Enovis (NYSE: ENOV) announced today that it appointed Davide Visentin as the new president of its International Surgical ...

Unfortunately, that's been the case for longer term Enovis Corporation (NYSE:ENOV) shareholders, since the share price is down 68% in the last three years, falling well short of the market return ...

Chicago, IL – January 24, 2025 – Today, Zacks Equity Research Equity are Enovis ENOV, Omnicell OMCL and Phreesia PHR. Link: ...

Enovis has named Davide Visentin as its new president of the international surgical business, according to a Jan. 17 report from Mass Device. Mr. Visentin will succeed Benjamin Reinmann, MD, beginning ...

On Monday, Enovis Corp (ENOV) stock saw a modest uptick, ending the day at $45.35 which represents a slight increase of $0.58 or 1.30% from the prior close of $44.77. The stock opened at $44.43 and ...

Enovis (ENOV), a global medical technology company, Friday, announced that Davide Visentin will take over as President of Enovis ...

In a report released yesterday, Vik Chopra from Wells Fargo reiterated a Buy rating on Enovis (ENOV – Research Report), with a price target of ...

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...